A Meta-analysis of Drug Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Disease

This study has been completed.
Sponsor:
Information provided by:
Catholic University of the Sacred Heart
ClinicalTrials.gov Identifier:
NCT01036048
First received: December 7, 2009
Last updated: December 18, 2009
Last verified: December 2009
  Purpose

A meta-analysis to compare outcomes of drug eluting stents (DES) versus bare metal stent (BMS) in saphenous vein graft (SVG) disease.


Condition Intervention
Saphenous Vein Graft Disease
Device: drug eluting stent
Device: bare metal stent

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Drug Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Disease: Insights From a Meta-analysis

Further study details as provided by Catholic University of the Sacred Heart:

Primary Outcome Measures:
  • death [ Time Frame: years depending from studies retrieved ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • myocardial infarction [ Time Frame: years depending from study retrieved ] [ Designated as safety issue: No ]
  • target vessel revascularization [ Time Frame: years depending from study retrieved ] [ Designated as safety issue: No ]

Enrollment: 5806
Study Start Date: May 2009
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
cabg disease
pts with saphenous vein graft disease
Device: drug eluting stent
pts with cabg disease treated with drug eluting stent
Other Name: des
Device: bare metal stent
pts with cabg disease treated with bare metal stent
Other Name: bms

Detailed Description:

To compare outcomes (death, myocardial infarction, target vessel revascularization) of drug eluting stent versus bare metal stent in saphenous vein graft disease.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients with CABG disease

Criteria

Inclusion Criteria:

  • CABG disease
  • randomized studies
  • not randomized studies

Exclusion Criteria:

  • studies reporting composite and not single endpoints, duplicate reporting
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01036048

Sponsors and Collaborators
Catholic University of the Sacred Heart
Investigators
Principal Investigator: ALESSANDRO LUPI, MD OSPEDALE MAGGIORE NOVARA
Principal Investigator: ELIANO NAVARESE, MD CATHOLIC UNIVERSITY OF SACRED HEART
  More Information

No publications provided by Catholic University of the Sacred Heart

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: navarese, Catholic University of the Sacred Heart
ClinicalTrials.gov Identifier: NCT01036048     History of Changes
Other Study ID Numbers: N28LBCF80-07
Study First Received: December 7, 2009
Last Updated: December 18, 2009
Health Authority: Italy: Ethics Committee

Keywords provided by Catholic University of the Sacred Heart:
saphenous vein graft
stent

ClinicalTrials.gov processed this record on August 19, 2014